NASDAQ:GLPG
Galapagos NV Stock News
$28.91
-0.310 (-1.06%)
At Close: Apr 18, 2024
Are Medical Stocks Lagging Galapagos (GLPG) This Year?
10:50am, Wednesday, 29'th Jun 2022
Here is how Galapagos NV (GLPG) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.
Galapagos neemt CellPoint en AboundBio over om toegang tot celtherapieën van de volgende generatie te versnellen
08:03pm, Tuesday, 21'st Jun 2022 GlobeNewswire Inc.
Webcast presentatie morgen, woensdag 22 juni 2022, om 14.00 CET / 8 AM ET, www.glpg.com
Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
08:03pm, Tuesday, 21'st Jun 2022 GlobeNewswire Inc.
Webcast presentation tomorrow, Wednesday, 22 June 2022, at 14.00 CET / 8 AM ET, www.glpg.com
Galapagos verhoogt kapitaal door uitoefening van inschrijvingsrechten
08:01pm, Monday, 20'th Jun 2022 GlobeNewswire Inc.
Mechelen, België; 20 juni 2022, 22.01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt een kapitaalverhoging aan als gevolg van de uitoefening van inschrijvingsrec
Galapagos increases share capital through subscription right exercises
08:01pm, Monday, 20'th Jun 2022 GlobeNewswire Inc.
Mechelen, Belgium; 20 June 2022, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.
Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA
02:42pm, Thursday, 16'th Jun 2022 Zacks Investment Research
The FDA issues briefing documents related to Acadia's (ACAD) resubmitted sNDA for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis. Shares rise.
Wall Street Analysts See a 28% Upside in Galapagos NV (GLPG): Can the Stock Really Move This High?
01:55pm, Thursday, 09'th Jun 2022 Zacks Investment Research
The consensus price target hints at a 28.3% upside potential for Galapagos NV (GLPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti
Wall Street Analysts See a 28% Upside in Galapagos NV (GLPG): Can the Stock Really Move This High?
11:17am, Thursday, 09'th Jun 2022
The consensus price target hints at a 28.3% upside potential for Galapagos NV (GLPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti
Is Galapagos (GLPG) Stock Outpacing Its Medical Peers This Year?
01:40pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Here is how Galapagos NV (GLPG) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
Is Galapagos (GLPG) Stock Outpacing Its Medical Peers This Year?
11:18am, Thursday, 02'nd Jun 2022
Here is how Galapagos NV (GLPG) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
Galapagos: Can The Company Turn Around?
01:18pm, Thursday, 19'th May 2022
Amid the biotech bear market, there are companies that are trading on a deep bargain, yet you should be extremely careful before averaging down. Though I noticed the fundamental changes in Galapagos,
Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year?
01:40pm, Monday, 16'th May 2022 Zacks Investment Research
Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year?
11:17am, Monday, 16'th May 2022
Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Perrigo (PRGO) Q1 Earnings Miss, Margins Hurt by Higher Costs
01:47pm, Wednesday, 11'th May 2022 Zacks Investment Research
Perrigo (PRGO) reports mixed first-quarter 2022 results. Sales of cough/cold products continue the strong rebound during the reported quarter. Costs headwinds offset volume and price growth.
RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value
07:30pm, Monday, 09'th May 2022 Benzinga
RBC Capital Markets views Galapagos' NV (NASDAQ: GLPG) Q1 Jyseleca revenues in line as the story focuses on whether new leadership can unlock value from GLPG's ample balance sheet.
Jyseleca's Q1 s
